Loading
A growth receptor amplified in squamous lung cancer and fused in a rare blood cancer. Pemigatinib is approved for the FGFR1-rearranged myeloid and lymphoid neoplasm, and pan-FGFR drugs block FGFR1 too, which is why they raise blood phosphate. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Receptor tyrosine kinase; gene amplification in squamous cancers and fusions in the 8p11 myeloproliferative syndrome; renal FGFR1 mediates the hyperphosphataemia of pan-FGFR inhibitors.
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Non-small-cell lung cancer | 17-22% | Focal high-level amplification | cBioPortal high-level amplification: 83 of 487, 17.0%, in lusc_tcga_pan_can_atlas_2018; 30 of 178, 16.9%, in lusc_tcga_pub; 102 of 1,144, 8.9%, in the combined nsclc_tcga_broad_2016; against 14 of 511, 2.7%, in lung adenocarcinoma. Amplification was found in a systematic copy-number search of 155 squamous cell lung cancers and confirmed by fluorescence in situ hybridisation in 22% of an independent squamous cohort (Weiss 2010). | cBioPortal (TCGA) |
| Non-small-cell lung cancer | about 20% | FGFR1 amplification in squamous cell carcinoma of the lung | Weiss and colleagues found focal FGFR1 amplification in about a fifth of squamous lung cancers and rarely in adenocarcinoma. | doi.org |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
No product in the corpus is aimed at this target yet.
No trial in the corpus names this target or one of its products.
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"FGFR1" OR ABSTRACT:"FGFR1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about FGFR1, not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/fgfr1.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/fgfr1.json. Licence CC BY-NC 4.0.